Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21623674 | 0.95 | SIGMAR1 (0.31) | SIGMAR1LMNACYP3A4GABRA1TSHR | |
| SCHEMBL3480504 | 0.93 | SIGMAR1 (0.31) | SIGMAR1SLC6A2 | |
| SCHEMBL21358779 | 0.86 | SIGMAR1 (0.45) | SIGMAR1SLC6A2 | |
| SCHEMBL435752 | 0.82 | SIGMAR1 (0.38) | SIGMAR1LMNACYP3A4GABRA1TSHR | |
| SCHEMBL28344667 | 0.82 | LMNA (0.31) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL5165513 | 0.81 | FDPS (0.32) | — | |
| SCHEMBL1696717 | 0.78 | OPRD1 (0.35) | SIGMAR1LMNACYP3A4GABRA1TSHR | |
| SCHEMBL28508077 | 0.77 | SLC6A2 (0.31) | SLC6A2 | |
| SCHEMBL16353882 | 0.77 | — | — | |
| SCHEMBL28408206 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021238893-A1 | EFFICIENT AND EFFECTIVE TISSUE CLEARING AGENTS AND THEIR COMPOSITIONS | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2021-12-02 | — | — | WO | claimed |
| US-20260144849-A1 | MEMBRANE FOR GUIDED BONE REGENERATION AND METHOD FOR MANUFACTURING THE SAME | Y-Bon Bio Inc. (KR) | 2026-05-28 | — | — | US | disclosed |
| US-20250060375-A1 | ALPHA-SYNUCLEIN DETECTION ASSAY | The Univ. Court of the Univ. of Edinburgh (GB) | 2025-02-20 | — | — | US | disclosed |
| US-20250011335-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2025-01-09 | — | — | US | disclosed |
| US-12122785-B2 | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors | SUDO BIOSCIENCES LIMITED (GB) | 2024-10-22 | — | — | US | disclosed |
| US-20240344023-A1 | HYDROXYUREA TO ENHANCE SPERM CELLS | MEHARRY MEDICAL COLLEGE (US) | 2024-10-17 | — | — | US | disclosed |
| WO-2024119440-A1 | BIODEGRADABLE MULTI-BLOCK COPOLYMERS COMPRISING LINKING UNITS DERIVED FROM CYCLIC KETENE ACETAL | BASF SE (DE) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024114687-A1 | ANTI-TFR1 ANTIBODIES AND USES THEREOF | BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024109307-A1 | A PHARMACEUTICAL COMPOSITION OF A RECOMBINANT ADENO-ASSOCIATED VIRUS VECTOR AND ITS APPLICATION | SICHUAN REAL & BEST BIOTECH CO., LTD. (CN) | 2024-05-30 | — | — | WO | disclosed |
| EP-4373945-A1 | COMPOSITIONS AND METHODS FOR EFFECTIVE DELIVERY OF POLYNUCLEOTIDES TO CELLS | Wuhan University (CN) | 2024-05-29 | — | — | EP | disclosed |
| US-5766879-A | ISOLATED NUCLEIC ACID MOLECULE ENCODING SEROTONIN RECEPTORS; DETERMINING LIGAND BINDING, DETECTING EXPRESSION, DRUG SCREENING | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| US-5721252-A | PIPERIDINYL-1H-INDOLE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-02-24 | — | — | US | disclosed |
| US-5708008-A | TREATMENT OF MIGRAINE | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| US-5708187-A | MIGRANE HEADACHES | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| US-5698571-A | ADMINISTERING TO THE MAMMAL A AGONIST WHICH POSSESSES A PREFERENTIAL SPECIFICITY INDEX; EXHIBIT MINIMUM VASOCONSTRICTIVE SIDE EFFECT | ELI LILLY AND COMPANY (US) | 1997-12-16 | — | — | US | disclosed |
| US-5698530-A | A VACCINIA VIRUS INTO WHICH CARCINOEMBRYONIC ANTIGEN GENE IS INSERTETED; INDUCE AN ACTIVE IMMUNE RESPONSE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-12-16 | — | — | US | disclosed |
| US-5693534-A | CULTURE MEDIUM COMPRISING HUMAN ACTIVIN AND INHIBIN | GENENTECH, INC. (US) | 1997-12-02 | — | — | US | disclosed |
| US-5503975-A | PREDICTING IN VITRO METHYLATION PATTERN OF DNA MOLECULE BY DETERMINING NUCLEOTIDE SEQUENCE, DETERMINING WHETHER SEQUENCE INCLUDES SPECIFIED SITE | CITY OF HOPE (US) | 1996-04-02 | — | — | US | disclosed |
| EP-0684997-A1 | ANTHRAX TOXIN FUSION PROTEINS AND USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-12-06 | — | — | EP | disclosed |
| WO-1994018332-A2 | ANTHRAX TOXIN FUSION PROTEINS AND USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12122785-B2 | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors | TYK2, JAK1, PDXK | SIGMAR1 4352/4885LMNA 2270/4885CYP3A4 1473/4885 |
| US-20250011335-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | SIGMAR1 4483/4885LMNA 2207/4885CYP3A4 1736/4885 |
| US-20240344023-A1 | HYDROXYUREA TO ENHANCE SPERM CELLS | NASP, ACR, CATSPER1 | SIGMAR1 2069/4885LMNA 1847/4885CYP3A4 4676/4885 |
| US-20260144849-A1 | MEMBRANE FOR GUIDED BONE REGENERATION AND METHOD FOR MANUFACTURING THE SAME | BMP2, BMPR2, BMPR1B | SIGMAR1 1380/4885LMNA 2006/4885CYP3A4 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.